Rankings
▼
Calendar
NVAX Q3 2022 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
Q3 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$735M
+310.7% YoY
Gross Profit
$300M
40.8% margin
Operating Income
-$127M
-17.3% margin
Net Income
-$169M
-23.0% margin
EPS (Diluted)
$-2.15
QoQ Revenue Growth
+295.1%
Cash Flow
Operating Cash Flow
-$39M
Free Cash Flow
-$68M
Stock-Based Comp.
$32M
Balance Sheet
Total Assets
$2.3B
Total Liabilities
$2.8B
Stockholders' Equity
-$566M
Cash & Equivalents
$1.3B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$735M
$179M
+310.7%
Gross Profit
$300M
$179M
+67.7%
Operating Income
-$127M
-$307M
+58.6%
Net Income
-$169M
-$322M
+47.7%
Revenue Segments
Product
$626M
85%
Grant
$106M
14%
Royalties and Other
$2M
0%
← FY 2022
All Quarters
Q4 2022 →